Late Phase - ICON plc

By: Icon Clinical Research (canada)  09-12-2011

Post-approval, non-interventional and observational studies can be used to address questions pertaining to safety surveillance, risk management and efficacy.  Correct study choice and effective execution are paramount to achieving the desired goals.

With a track record for successful analysis and extensive scientific publication, the ICON Late Phase & Outcomes Research division delivers high-impact evidence that explores and demonstrates the value of pharmaceutical, biotechnology, consumer healthcare and medical device products in all global markets, with a focus on maximising return on investment

Our global team of experts provide a full spectrum of market-leading clinical Late Phase research, real-world studies, health economics and patient reported outcomes to support our clients’ product lifecycle, from early stage development, pricing and market access strategies, through regulatory and reimbursement approvals, labeling claims, and in-market support

Contact Icon Clinical Research (canada)


Print this page

Other products and services from Icon Clinical Research (canada)


Laboratories - ICON plc

All ICON laboratories use state of the art instrumentation and equipment and are either GCP or GLP as well as CAP accredited. Learn more about our laboratory capabilities by visiting the different laboratory sections shown on the left of this page. ICON provides a full range of laboratory services that are dedicated exclusively to clinical development.


Clinical Pharmacology, Early Phase Development, First in Human Trial

Our multi-disciplinary experts have the experience to address the most demanding drug development challenges with an unyielding focus on completing projects on time, on budget and with the quality that will withstand the most vigorous scrutiny.